- Conditions
- Venous Thromboembolism
- Interventions
- Electronic alert
- Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bleeding
- Interventions
- Andexanet alfa (bolus), Betrixaban 80 mg PO QD, Andexanet alfa (infusion IV)
- Biological · Drug
- Lead sponsor
- Portola Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Atrial Fibrillation
- Interventions
- betrixaban, Warfarin
- Drug
- Lead sponsor
- Portola Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 508 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 19
- States / cities
- Anaheim, California • Colorado Springs, Colorado • Melbourne, Florida + 16 more
- Conditions
- Venous Thromboses
- Interventions
- Not listed
- Lead sponsor
- Portola Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Venous Thromboembolism (VTE)
- Interventions
- Betrixaban, Enoxaparin
- Drug
- Lead sponsor
- Portola Pharmaceuticals
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 7,513 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Bakersfield, California • Fresno, California + 69 more
- Conditions
- VTE Prophylaxis
- Interventions
- Betrixaban
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Atlanta, Georgia • New Orleans, Louisiana + 1 more
- Conditions
- Hepatic Impairment
- Interventions
- Betrixaban
- Drug
- Lead sponsor
- Portola Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Hialeah, Florida
- Conditions
- Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA
- Interventions
- LAmbre PlusTM Left Atrial Appendage Closure System, Market approved oral anticoagulation (OAC), such as warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixiban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)
- Device · Drug
- Lead sponsor
- Brian O'Neill MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Detroit, Michigan